An open-label, randomized, single-dose, four-treatment crossover study to evaluate platelet function in healthy adult male volunteers following administration of intravenous diclofenac sodium (DIC075V 37.5 mg) [Dyloject], oral diclofenac potasssium (Cataflam 50 mg), intravenous ketorolac tromethamine 30 mg and acetylsalicylic acid (ASA 325 mg) [aspirin]

Trial Profile

An open-label, randomized, single-dose, four-treatment crossover study to evaluate platelet function in healthy adult male volunteers following administration of intravenous diclofenac sodium (DIC075V 37.5 mg) [Dyloject], oral diclofenac potasssium (Cataflam 50 mg), intravenous ketorolac tromethamine 30 mg and acetylsalicylic acid (ASA 325 mg) [aspirin]

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jan 2010

At a glance

  • Drugs Aspirin; Diclofenac; Diclofenac potassium; Ketorolac
  • Indications Musculoskeletal pain; Osteoarthritis; Rheumatoid arthritis
  • Focus Pharmacodynamics
  • Sponsors Javelin Pharmaceuticals
  • Most Recent Events

    • 09 Jan 2008 Status change from recruiting to completed.
    • 03 Nov 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top